• Mashup Score: 54

    Regeneron has a long history with its gene-sequencing efforts, which likely provides some hints as to why the biotech saw the 23andMe deal as worthwhile.

    Tweet Tweets with this article
    • Regeneron's 23andMe buyout is the best possible outcome. A Big Pharma would just bobble it, then watch it die. REGN is far more purposeful and directed. They get it cheap, keep their eyes on the ball and manage things. I like it. https://t.co/PwOyG1zOd8